Targeted agents in ovarian cancer

Women's Health

Volumn 6, Issue 5, 2010, Pages 679-694

  Kristedja, T S ^a   Morgan, R J ^a   Cristea, M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

ovarian cancer; targeted agents

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; AFLIBERCEPT; BEVACIZUMAB; BIBF 1120; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; OLAPARIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; PLATINUM COMPLEX; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VOTRIENT;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PROTEINURIA; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 77957735000     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.48     Document Type: Review

References (123)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. American Cancer Society: Cancer Facts & Figures 2009. American Cancer Society, Atlanta (2009).
3. Young RC, Walton LA, Ellenberg SS et al.: Adjuvant therapy in grade I and grade II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. 322(15), 1021-1027 (1990).
4. McGuire WP, Hoskins WJ, Brady MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with grade III and grade IV ovarian cancer. N. Engl. J. Med. 334(1), 1-6 (1996).
5. Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected grade III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21(17), 3194-3200 (2003).
6. Vasey PA, Jayson GC, Gordon A et al.: Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as frst-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96(22), 1682-1691 (2004).
7. Bookman MA, Brady MF, McGuire WP et al.: Evaluation of new platinum-based treatment regimens in advanced-grade ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27(9), 1419-1425 (2009).
8. Alberts DS, Liu PY, Hannigan EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for grade III ovarian cancer. N. Engl. J. Med. 335(26), 1950-1955 (1996).
9. Armstrong DK, Bundy B, Wenzel L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354(1), 34-43 (2006).
10. Markman M, Bundy BN, Alberts DS et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume grade III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19(4), 1001-1007 (2001).
11. Rao G, Crispens M, Rothenberg ML: Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J. Clin. Oncol. 25(20), 2867-2872 (2007).
12. Armstrong DK: Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7(Suppl. 5), 20-28 (2002).
13. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl. 1), 2-10 (2004).
14. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
15. Cooper BC, Ritchie JM, Broghammer CL et al.: Preoperative serum vascular endothelial growth factor levels: signifcance in ovarian cancer. Clin. Cancer Res. 8(10), 3193-3197 (2002).
16. Frumovitz M, Sood AK: Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol. Oncol. 104(3), 768-778 (2007).
17. Hefer LA, Zeillinger R, Grimm C et al.: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol. Oncol. 103(2), 512-517 (2006).
18. Paley PJ, Staskus KA, Gebhard K et al.: Vascular endothelial growth factor expression in early grade ovarian carcinoma. Cancer 80(1), 98-106 (1997).
19. Shen GH, Ghazizadeh M, Kawanami O et al.: Prognostic signifcance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 83(2), 196-203 (2000).
20. Cannistra SA, Matulonis UA, Penson RT et al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25(33), 5180-5186 (2007).
21. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
22. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 25(33), 5165-5171 (2007).
23. Hapani S, Chu D, Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 10(6), 559-568 (2009).
24. Burger RA: Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 25(20), 2902-2908 (2007).
25. Friberg G, Oza AM, Morgan RJ, Vokes EE, Gandara DR, Fleming GF: Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer: preliminary results of a multi-center Phase II trial. J. Clin. Oncol. 24(Suppl. 18S), (2006).
26. Sandler A, Gray R, Perry MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
27. Garcia AA, Hirte H, Fleming G et al.: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J. Clin. Oncol. 26(1), 76-82 (2008).
28. McGonigle KF, Muntz HG, Vuky JL et al.: Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer. J. Clin. Oncol. 26(Suppl. 15), 5551 (2008).
29. Kikuchi Y, Kouta H, Kikuchi R et al.: Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer. J. Clin. Oncol. 27(Suppl. 15), 5547 (2009).
30. Muggia FM, Boyd L, Liebes L et al.: Pegylated liposomal doxorubicin with bevacizumab in second-line treatment of ovarian cancer: pharmacokinetics, safety, and preliminary outcome results. J. Clin. Oncol. 27(Suppl. 15), 5548 (2009).
31. Micha JP, Goldstein BH, Rettenmaier MA et al.: A Phase II study of outpatient frst-line paclitaxel, carboplatin, and bevacizumab for advanced-grade epithelial ovarian, peritoneal, and fallopian tube cancer. Int. J. Gynecol. Cancer 17(4), 771-776 (2007).
32. Rose PG, Drake R, Braly PS et al.: Preliminary results of a Phase II study of oxaliplatin, docetaxel, and bevacizumab as frst-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J. Clin. Oncol. 27(Suppl. 15), 5546 (2009).
33. Konner JA, Grabon D, Pezzulli S et al.: A Phase II study of intravenous (IV) and intraperitoneal (ip) paclitaxel, ip cisplatin, and iv bevacizumab as frst-line chemotherapy for optimal grade II or III ovarian, primary peritoneal, and fallopian tube cancer. J. Clin. Oncol. 27(Suppl. 15), 5539 (2009).
34. McMeekin DD, Lanneau G, Curiel J, Moore K, Walker J, Mannel R: Phase II study of intravenous bevacizumab and paclitaxel, and intraperitoneal cisplatin, followed by bevacizumab consolidation for advanced ovarian or peritoneal cancers. J. Clin. Oncol. 27(Suppl. 15), (2009).
35. Byrne AT, Ross L, Holash J et al.: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 9(15), 5721-5728 (2003).
36. Tew WP, Colombo N, Ray-Coquard I et al.: VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: Preliminary results of a randomized, multicenter Phase II study. J. Clin. Oncol. 25(Suppl. 18), 5508 (2007).
37. Wedge SR, Kendrew J, Hennequin LF et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).
38. Drevs J, Siegert P, Medinger M et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(21), 3045-3054 (2007).
39. Laurie SA, Gauthier I, Arnold A et al.: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 26(11), 1871-1878 (2008).
40. Ryan CJ, Stadler WM, Roth B et al.: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest. New Drugs 25(5), 445-451 (2007).
41. Matulonis UA, Berlin S, Ivy P et al.: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601-5606 (2009).
42. Hirte HW, Vidal L, Fleming GF et al.: A Phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: fnal results of a PMH, Chicago and California consortia trial. J. Clin. Oncol. 26(Suppl.), 5521 (2008).
43. Friedlander M, Hancock KC, Benigno B et al.: Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a Phase II study J. Clin. Oncol. 25(Suppl.18), 5561 (2007).
44. Mendel DB, Laird AD, Xin X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003).
45. O'Farrell AM, Abrams TJ, Yuen HA et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9), 3597-3605 (2003).
46. Biagi JJ, Oza AM, Grimshaw R et al.: A Phase II study of sunitinib (SU11248) in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185. J. Clin. Oncol. 26(Suppl. 15), 5522 (2008).
47. Rustin GJ, Galbraith SM, Anderson H et al.: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21(15), 2815-2822 (2003). (Pubitemid 46621828)
48. West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 15(3), 179-187 (2004).
49. Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC: Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res. 23(2B), 1619-1623 (2003).
50. Zweifel M, Jayson G, Reed N et al.: Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: fnal Phase II trial results. J. Clin. Oncol. 27(Suppl. 15), (2009).
51. Ledermann JA, Rustin GJ, Hackshaw A et al.: A randomized Phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. J. Clin. Oncol. 27(Suppl. 15), 5501 (2009).
52. Ciardiello F, Caputo R, Damiano V et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546-1556 (2003).
53. Beebe JS, Jani JP, Knauth E et al.: Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 63(21), 7301-7309 (2003).
54. Burgess AW, Cho HS, Eigenbrot C et al.: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12(3), 541-552 (2003).
55. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J. Natl Cancer Inst. 93(18), 1375-1384 (2001).
56. Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM: Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor α in epithelial ovarian cancer. Eur. J. Gynaecol. Oncol. 17(6), 487-492 (1996).
57. Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E: Epidermal growth factor receptor and transforming growth factor α expression in human ovarian carcinomas. Eur. J. Cancer 28A(8-9), 1432-1437 (1992).
58. Skirnisdottir I, Sorbe B, Seidal T: The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early grade (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 11(2), 119-129 (2001).
59. Fischer-Colbrie J, Witt A, Heinzl H et al.: EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17(1B), 613-619 (1997).
60. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), 9-15 (2001).
61. Gordon AN, Finkler N, Edwards RP et al.: Effcacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer 15(5), 785-792 (2005).
62. Perez-Soler R, Chachoua A, Hammond LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238-3247 (2004).
63. Vasey PA, Gore M, Wilson R et al.: A Phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br. J. Cancer 98(11), 1774-1780 (2008).
64. Posadas EM, Liel MS, Kwitkowski V et al.: A Phase II and pharmacodynamic study of geftinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7), 1323-1330 (2007).
65. Schilder RJ, Sill MW, Chen X et al.: Phase II study of geftinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11(15), 5539-5548 (2005).
66. Wagner U, du Bois A, Pfsterer J et al.: Geftinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a Phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol. Oncol. 105(1), 132-137 (2007).
67. Konner J, Schilder RJ, DeRosa FA et al.: A Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-grade ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110(2), 140-145 (2008).
68. Schilder RJ, Pathak HB, Lokshin AE et al.: Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 113(1), 21-27 (2009).
69. Secord AA, Blessing JA, Armstrong DK et al.: Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol. Oncol. 108(3), 493-499 (2008).
70. Susman E: Rash correlates with tumour response after cetuximab. Lancet Oncol. 5(11), 647 (2004).
71. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplifcation of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
72. Tuefferd M, Couturier J, Penault-Llorca F et al.: HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS one 2(11), e1138 (2007).
73. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21(2), 283-290 (2003).
74. Ray-Coquard I, Guastalla JP, Djelila A et al.: HER2 overexpression/ amplifcation and trastuzumab treatment in advanced ovarian cancer: A GINECO Phase II study. Clin. Ovarian Cancer Special Issue 17-22 (2009).
75. Agus DB, Akita RW, Fox WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer cell 2(2), 127-137 (2002).
76. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer cell 5 (4), 317-328 (2004).
77. Gordon MS, Matei D, Aghajanian C et al.: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24(26), 4324-4332 (2006).
78. Makhija S, Amler LC, Glenn D et al.: Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. J. Clin. Oncol. 28(7), 1215-1223 (2009).
79. Joly F, Weber B, Pautier P et al.: Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after frst line of platinum-based chemotherapy: a French FEDEGYN-FNCLCC Phase II trial. J. Clin. Oncol. 27(Suppl. 15S), 5555 (2009).
80. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7(7), 517-528 (2006).
81. Schultz N, Lopez E, Saleh-Gohari N, Helleday T: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31(17), 4959-4964 (2003).
82. Iglehart JD, Silver DP: Synthetic lethality-a new direction in cancer-drug development. N. Engl. J. Med. 361(2), 189-191 (2009).
83. Fong PC, Boss DS, Yap TA et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
84. Audeh MW, Penson RT, Friedlander M et al.: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-defcient advanced ovarian cancer. J. Clin. Oncol. 25(Suppl. 15S) (2009).
85. Nguewa PA, Fuertes MA, Cepeda V et al.: Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatinresistant tumor cells. Med. Chem. (Shariqah (United Arab Emirates)), 2(1), 47-53 (2006).
86. Rottenberg S, Jaspers JE, Kersbergen A et al.: High sensitivity of BRCA1-defcient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105(44), 17079-17084 (2008).
87. Sakai W, Swisher EM, Karlan BY et al.: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182), 1116-1120 (2008).
88. Ebel W, Routhier EL, Foley B et al.: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-α. Cancer Immun. 7, 6 (2007).
89. Kalli KR, Oberg AL, Keeney GL et al.: Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108(3), 619-626 (2008).
90. Armstrong DK, Bicher A, Coleman RL et al.: Exploratory Phase II effcacy study of MORAb-003, a monoclonal antibody against folate receptorα, in platinum-sensitive ovarian cancer in frst relapse. J. Clin. Oncol. 26(Suppl. 15), 5500 (2008).
91. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al.: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66(11), 5549-5554 (2006).
92. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6(9), 729-734 (2006).
93. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5(8), 671-688 (2006).
94. Steelman LS, Stadelman KM, Chappell WH et al.: Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 12(9), 1139-1165 (2008).
95. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
96. Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24(35), 5601-5608 (2006).
97. Noske A, Lindenberg JL, Darb-Esfahani S et al.: Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol. Rep. 20(6), 1409-1417 (2008).
98. Zhang HY, Zhang PN, Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur. J. Obstet. Gynecol. Reprod. Biol. 146(1), 81-86 (2009).
99. Mabuchi S, Altomare DA, Cheung M et al.: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 13(14), 4261-4270 (2007).
100. Huynh H, Teo CC, Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol. Cancer Ther. 6(11), 2959-2966 (2007).
101. Trinh XB, Tjalma WA, Vermeulen PB et al.: The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer, 100(6), 971-978 (2009).
102. Hatch KD, Beecham JB, Blessing JA, Creasman WT: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68(2), 269-271 (1991).
103. Williams CJ: Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst. Rev. (2), CD001034 (2000).
104. Perez-Gracia JL, Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84(2), 201-209 (2002).
105. Geisinger KR, Berens ME, Duckett Y, Morgan TM, Kute TE, Welander CE: The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 65(5), 1055-1061 (1990).
106. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB: Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int. J. Cancer 55(6), 1018-1022 (1993).
107. Panasci L, Jean-Claude BJ, Vasilescu D et al.: Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem. Pharmacol. 52(7), 1097-1102 (1996).
108. Benedetti Panici P, Greggi S, Amoroso M et al.: A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int. J. Gynecol. Cancer 11(6), 438-444 (2001).
109. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J: Phase II trial of carboplatin plus tamoxifen in platinumresistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol. Oncol. 94(2), 404-408 (2004). (Pubitemid 39024545)
110. del Carmen MG, Fuller AF, Matulonis U et al.: Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol. Oncol. 91(3), 596-602 (2003).
111. Papadimitriou CA, Markaki S, Siapkaras J et al.: Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a Phase II study. Oncology 66(2), 112-117 (2004).
112. Smyth JF, Gourley C, Walker G et al.: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13(12), 3617-3622 (2007).
113. Verma S, Alhayki M, Le T et al.: Phase II study of exemestane in refractory ovarian cancer. J. Clin. Oncol. 24 (Suppl. 18), (2006).
114. Argenta PA, Thomas SG, Judson PL et al.: A Phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol. Oncol. 113(2), 205-209 (2009).
115. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352(9132), 930-942 (1998).
116. Fisher B, Costantino J, Redmond C et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320(8), 479-484 (1989). (Pubitemid 19062522)
117. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
118. Cortes-Funes H, Gomez C, Rosell R et al.: Epidermal growth factor receptor activating mutations in Spanish geftinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16(7), 1081-1086 (2005).
119. Han SW, Kim TY, Hwang PG et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with geftinib. J. Clin. Oncol. 23(11), 2493-2501 (2005).
120. Mitsudomi T, Kosaka T, Endoh H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after geftinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23(11), 2513-2520 (2005).
121. Gore ME, Escudier B: Emerging effcacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 20(6 Suppl 5), 19-24 (2006).
122. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ: Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br. J. Clin. Pharmacol. 62(1), 15-26 (2006). (Pubitemid 44195239)
123. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).